Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CIZNASDAQ:KLDONASDAQ:MTFBCVE:PAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCIZVictoryShares Developed Enhanced Volatility Wtd ETF$31.42-0.3%$30.44$28.17▼$32.17$42.42M0.615,792 shs7,247 shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.03$4K-0.065,586 shs1,954 shsMTFBMOTIF BIO PLC/S$0.11$0.10$0.08▼$11.50N/AN/AN/A867,698 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCIZVictoryShares Developed Enhanced Volatility Wtd ETF+0.54%+0.05%+3.03%+4.41%+3,150,999,900.00%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%MTFBMOTIF BIO PLC/S0.00%0.00%0.00%0.00%0.00%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCIZVictoryShares Developed Enhanced Volatility Wtd ETF0.00N/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/AN/AN/AN/AN/AN/AKLDOKaleido Biosciences$1.10M0.00N/AN/AN/A∞MTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/AN/A12.15∞N/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/A0.00∞N/AN/AN/AN/AN/APASPascal BiosciencesN/A-C$0.01N/A∞N/AN/AN/A-340.40%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCIZVictoryShares Developed Enhanced Volatility Wtd ETF$1.013.21%N/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ALatest MTFB, PYC, PAS, CIZ, and KLDO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/8/2024CIZVictoryShares Developed Enhanced Volatility Wtd ETFMonthly$0.05243/11/20243/12/20243/13/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AMTFBMOTIF BIO PLC/SN/AN/AN/APASPascal Biosciences882.790.030.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/AKLDOKaleido Biosciences81.56%MTFBMOTIF BIO PLC/SN/APASPascal BiosciencesN/AInsider OwnershipCompanyInsider OwnershipCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/AKLDOKaleido Biosciences9.00%MTFBMOTIF BIO PLC/SN/APASPascal Biosciences15.43%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCIZVictoryShares Developed Enhanced Volatility Wtd ETFN/A1.35 millionN/ANot OptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionableMTFBMOTIF BIO PLC/S7N/AN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableMTFB, PYC, PAS, CIZ, and KLDO HeadlinesSourceHeadlinePedro Pascal Wraps 'The Last Of Us' Season 2 Filming In Record Time: What It Means For Joel's Fatemsn.com - March 27 at 7:48 PMThe Last Of Us 2 Fans Mock Pedro Pascal's Short Filming Stint On Season 2msn.com - March 27 at 2:48 PMPascal Struijk: Leeds United defender out for season after groin surgerybbc.co.uk - March 27 at 2:48 PMThe Last of Us Season 2 gets surprising Pedro Pascal updatemsn.com - March 27 at 2:48 PMPacers forward Pascal Siakam nominated for Eastern Conference Player of the Week againathlonsports.com - March 27 at 9:48 AMBulls aiming to contain Pacers' red-hot Pascal Siakamcbssports.com - March 27 at 9:48 AMHBO denies rumors that Pedro Pascal has finished filming Season 2 of «The Last of Us»itc.ua - March 27 at 9:48 AMThe Last Of Us Fans Fear The Worst After Pedro Pascal Filming Update, But I Have A More Optimistic Theorymsn.com - March 27 at 9:48 AMWhy Pedro Pascal's The Last of Us Schedule Became a Major Storymsn.com - March 27 at 9:48 AMPascal Siakam NBA Player Preview vs. the Bulls - March 2714news.com - March 27 at 9:48 AMPascal Siakam discusses his 31-point effort and the Pacers win over the Clippers.indystar.com - March 26 at 9:50 AMThe Last of Us fans fear the worst as Pedro Pascal wraps filming for Season 2dexerto.com - March 26 at 4:50 AMPascal Siakam helps Pacers pull away from Clippers for 133-116 winmsn.com - March 26 at 4:50 AMLeeds United reach Pascal Struijk surgery deadline as potential season-ending decision set for revealmsn.com - March 25 at 6:48 PMPascal Siakam Player Prop Bets: Pacers vs. Clippers | March 25sportsbookwire.usatoday.com - March 25 at 6:48 PMPascal Siakam NBA Player Preview vs. the Clippers - March 25wkyt.com - March 25 at 6:48 PMPacers forward Pascal Siakam discusses his 36-point effort in a loss to Los Angeles.indystar.com - March 25 at 9:03 AMOne Star Wars Scene Is Pedro Pascal’s Best In The Mandalorian – Can It Ever Be Equalled?thetechedvocate.org - March 25 at 9:03 AMPascal Amanfo ties the knot, shares stunning photosmyjoyonline.com - March 25 at 9:03 AMPascal Siakam's 36-point paint domination shows how he's changed the Pacers' approachmsn.com - March 25 at 9:03 AMWhat We Know about Pedro Pascal’s Sister, Lux Pascalprestigeonline.com - March 25 at 4:02 AMPascal Siakam NBA Player Preview vs. the Lakers - March 24fox19.com - March 24 at 8:51 AM‘Why not?’ – Pascal Dupraz puts himself in race to succeed Hervé Renard as Les Bleues managergetfootballnewsfrance.com - March 23 at 5:49 PMThe Forgotten Pedro Pascal TV Series Role That Saved His Hollywood Careermsn.com - March 23 at 5:49 PMMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Watch for Tech Giants to Boost Share Buybacks in 2024March 15, 2024 9:59 AMView Watch for Tech Giants to Boost Share Buybacks in 2024Disney Stock is Ridiculously Cheap Now That the Worst is PastMarch 4, 2024 7:00 AMView Disney Stock is Ridiculously Cheap Now That the Worst is PastRoss Stores a Pre-earnings Buy with this Specific Strategy?February 29, 2024 7:00 AMView Ross Stores a Pre-earnings Buy with this Specific Strategy?All Headlines Company DescriptionsVictoryShares Developed Enhanced Volatility Wtd ETFNASDAQ:CIZThe VictoryShares Developed Enhanced Volatility Wtd ETF (CIZ) is an exchange-traded fund that mostly invests in large cap equity. The fund tracks an index of 500 ex-US developed-market stocks screened for positive earnings weighted by volatility. The fund can hold up to 75% cash in market downturns. CIZ was launched on Oct 1, 2014 and is managed by VictoryShares.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.MOTIF BIO PLC/SNASDAQ:MTFBMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.Pascal BiosciencesCVE:PASPascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.